Cancer biomarkers

Total PSA in prostate cancer
Prostate-specific antigen (PSA) is one of the most studied tumor markers. Elevated PSA levels can suggest the possibility of prostate cancer, but elevations may also occur in benign conditions such as benign prostatic hyperplasia or prostatitis. PSA testing is used by clinicians in shared decision-making about further evaluation, including imaging and biopsy, particularly in defined age and risk groups rather than as universal screening for all men.

CA 125 in ovarian cancer
Cancer antigen 125 (CA 125) has been used for decades in ovarian cancer care. It can help monitor disease and evaluate response to therapy in patients already diagnosed with ovarian cancer. However, for individuals at average risk who have no symptoms, CA 125 is not recommended as a general screening test because it has not been shown to reduce mortality and may lead to false positives and unnecessary procedures.

For laboratory professionals and assay developers, these markers underscore a broader principle in oncology diagnostics: analytical consistency and appropriate clinical interpretation are essential for meaningful application.

At AbBaltis, we supply materials for cancer marker assays including Total PSA and CA 125, supporting reliable testing within evidence-aligned clinical frameworks.

Explore our product catalogue:
https://lnkd.in/eArWt5_X

For more information:
info@abbaltis.com